Tuesday, July 14, 2020 5:08:27 PM
All longs need to take a good look at what they own. Biotech led the tech sector in the late 90's by more than double other tech.
We are in a huge bull market temporarily upset by Corona. Market has already returned 40% since the 19 day sell off at the beginning of the Corona melt down. A bull market with more innovation than any other time in history led by a President who is a businessman and progressive. We will see a big cut in capital gains tax.
So we are in the best of the best sectors to invest at an unprecedented time.
The company is basically unknown and the stock is a super bargain.
The company has the new science that works in a number of indications with more to be discovered, as if HIV and Cancer weren't big enough.
It is the next generation monotherapy. Others biotechs will pay big bucks to hook on for the ride.
We are with a company that is no flash in the pan. 20-40 years easily and longer as new developments open up with Leronlimab.
We are at the brink of front page news. Wait until some large bonified research membership organizations with hundreds of thousands paid subcribers give the CYDY buy recommendation.
We are the best stock in the best sector in the best market and few know who we are. That all is about to change. It is going to be a nice long ride that has already begun to smooth out.
We are in a huge bull market temporarily upset by Corona. Market has already returned 40% since the 19 day sell off at the beginning of the Corona melt down. A bull market with more innovation than any other time in history led by a President who is a businessman and progressive. We will see a big cut in capital gains tax.
So we are in the best of the best sectors to invest at an unprecedented time.
The company is basically unknown and the stock is a super bargain.
The company has the new science that works in a number of indications with more to be discovered, as if HIV and Cancer weren't big enough.
It is the next generation monotherapy. Others biotechs will pay big bucks to hook on for the ride.
We are with a company that is no flash in the pan. 20-40 years easily and longer as new developments open up with Leronlimab.
We are at the brink of front page news. Wait until some large bonified research membership organizations with hundreds of thousands paid subcribers give the CYDY buy recommendation.
We are the best stock in the best sector in the best market and few know who we are. That all is about to change. It is going to be a nice long ride that has already begun to smooth out.
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
